|
The latest Mainline newsletters for the General Public are listed here. |
For healthcare professionals we have a Mainline newsletter in a Professional version here. |
Mainline |
||
| Volume 2 | November 11, 2005 | Number8 |
An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service |
||
Medication News & Update
FDA criticizes Cymbalta's medical journal ads
The FDA said that Eli Lilly & Co. failed to make the risks of its drug, Cymbalta, an antidepressant drug clear enough in medical journal advertisements. These advertisements were promoting the use of the drug for effects other than treatment of depression. They were promoting the drugs ability to treat pain associated with nerve problems resulting from diabetes. The representative from Eli Lilly indicated that the ads will no longer run.
 |
|
[ Home ]
[ About Us ]
[ Assessment Tools ]
[ Sample Consult ] |
